110 results about "Human breast" patented technology

The invention provides a beta '-sulfo-alpha, beta-unsaturated gamma-lactam derivative as well as a preparation method and application thereof, and belongs to the technical field of organic chemical synthesis. The beta '-thio-alpha, beta-unsaturated gamma-lactam derivative has a structure as shown in a formula I. According to the method disclosed by the invention, cesium carbonate is taken as alkali, and a molecular skeleton of the beta'-thio-alpha, beta-unsaturated gamma-lactam derivative is constructed through free radical coupling and olefin isomerization processes under the condition of blue light irradiation. Bioactivity evaluation shows that the beta '-sulfo-alpha, beta-unsaturated gamma-lactam derivative prepared by the method disclosed by the invention has an inhibition effect on MDA-MB-231 human breast cancer cells.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 3-sulfamoyl benzamide compound as well as a preparation method and application thereof. The 3-sulfamoyl benzamide compound has a structure as shown in a formula I. In the formula I, X is chlorine or trifluoromethyl; r1 and R2 are independently C1-4 alkyl or R1, R2 and N atoms connected with R1 and R2 jointly form a heterocyclic group, and the heterocyclic group is a substituted or unsubstituted five-membered or six-membered heterocyclic group; and when the heterocyclic group is a substituted heterocyclic group, the substituent group in the substituted heterocyclic group is one or more of C1-4 alkyl, phenyl and acetyl. The 3-sulfamoyl benzamide compound disclosed by the invention has a remarkable proliferation inhibition effect on HCT116 colon cancer cells, HeLa human cervical cancer cells, MDA-MB-231 human breast cancer cells and A375 human malignant melanoma cells.

The invention belongs to the technical field of machine learning, and provides a multi-model integrated prediction method and system for human breast cancer cytotoxicity caused by ionic liquid, and the main scheme is as follows: collecting experimental data and preprocessing the experimental data; splicing the quantifiable features to form an original feature matrix; performing feature dimension reduction processing on the original features to form an input feature matrix; taking the input feature matrix as input data, training a random forest, XGBoost and MLP basic machine learning model and carrying out model parameter adjustment, carrying out model integration on the trained basic machine learning model based on a weighted average fusion strategy, and selecting an optimal integrated model; evaluating the trained basic machine learning model, and applying the optimal integrated model to prediction of the human breast cancer cell toxicity of the ionic liquid of a new sample; and carrying out model deployment on the trained basic machine learning model and the selected optimal integrated model.

The application belongs to the technical field of medicine, and relates to N-methyl-2-(9-oxoacridin-10(9H)-yl)acetamide compounds and a preparation method and application thereof. The preparation method of the compound is as follows: taking o-aminobenzoic acid as a starting material, performing substitution reaction, condensation reaction, alkylation reaction and hydrolysis reaction to generate a key intermediate acridone acetic acid, and finally performing condensation reaction on the acridone acetic acid and substituted pyrimidine in the presence of TCFH and NMI condensing agents to obtain the target compound. The preparation method of the N-methyl-2-(9-oxoacridin-10(9H)-yl)acetamide compound provided in the application is simple and feasible, and good results are shown in in-vitro anti-tumor activity tests, and the compound has excellent anti-proliferation ability on human breast cancer cells BT-549 and MDA-MB-231 in particular.

The invention belongs to the technical field of pharmacy, and particularly relates to application of polycyclic alkaloid in preparation of an anti-breast cancer drug, and the polycyclic alkaloid is 1, 2a, 7-trimethyl-5-tosyl-1, 2, 2a, 3, 4, 5-hexahydropyrrolo [4, 3, 2-de] quinoline. The polycyclic alkaloid compound is applied to preparation of anti-breast cancer drugs, the effect of inhibiting growth of breast cancer cells is remarkable, and the efficacy of the polycyclic alkaloid compound is far better than that of a positive drug ML162 aiming at EC50 (mu M) + / -S.D = 9.04 + / -0.37 of HCC1937 human breast cancer cells.

The invention discloses an application of an ARRB1 inhibitor in preparation of a tumor drug resistance reversal agent or a tumor drug sensitizer. It is found that by reducing ARRB1 expression, the sensitivity of human breast cancer cells to etoposide can be improved, the drug resistance of breast cancer etoposide can be reversed, and an ARRB1 inhibitor can be combined with an anti-tumor drug etoposide for use to improve the treatment effect. The invention provides a new direction for research and development of drugs for overcoming breast cancer treatment drug resistance, and has important clinical application value and development value.

A method of inhibiting a cancer cell growth includes contacting the cancer cell with a Cu2(OH)3NO3 / CaSiO3@g-C3N4 nanocomposite material containing graphitic carbon nitride (g-C3N4), copper hydroxide nitrate (Cu2(OH)3NO3) and calcium silicate (CaSiO3), achieving an inhibition efficiency on human breast carcinoma (MCF-7) and human hepatocellular carcinoma (HepG-2) cell growth of greater than 95% in an in-vitro cellular viability assay.

The invention discloses a breast pump. The breast pump comprises at least one detection module, a processing module, a breast pumping shield, a breast pumping channel part and a negative pressure mechanism, the breast suction shield comprises a flange used for being attached to a human breast body. The breast sucking channel part is in sealed connection with the breast sucking shield and is used for accommodating a nipple and allowing milk to flow; the negative pressure mechanism is used for directly or indirectly applying negative pressure into the breast pumping channel part; the detection module is used for detecting brightness change caused by movement of a target object in the breast pumping shield or the breast pumping channel part and generating detection data, and the processing module is used for determining breast pumping related parameters according to the detection data. The detection module generates the detection data by detecting the brightness change caused by the movement of the target object, and the generated detection data is less influenced by the individual difference of the mother, so that the measurement interference caused by the difference of different individuals can be effectively avoided, and the finally determined breast pumping related parameters can be more accurate.

This invention relates to drug-resistant breast cancer cells and their applications, belonging to the field of tumor cell technology. The drug-resistant breast cancer cells of this invention are human mammary ductal carcinoma cells T47DR and / or human breast cancer cells MCF7R. The human mammary ductal carcinoma cells T47DR were deposited at the Guangdong Provincial Microbial Culture Collection Center on October 25, 2024, with accession number GDMCC No: 65348; the human breast cancer cells MCF7R were deposited at the same center on October 25, 2024, with accession number GDMCC No: 65347. This invention demonstrates that the clonogenic ability, migration ability, anti-apoptotic ability, and spheroidization ability of drug-resistant breast cancer cells are significantly enhanced. They can form tumors independently of estrogen and metastasize throughout the body in a short period of time. The tumor stemness of the drug-resistant cells is enhanced, and they exhibit resistance to apelexifen and / or tamoxifen.

Disclosed in the present invention are a PARP1 / CDK6 dual-target inhibitor, and a preparation method therefor and the use thereof. The PARP1 / CDK6 dual-target inhibitor is a compound having a structure represented by formula I, or a pharmaceutically acceptable salt or solvate thereof, wherein L is selected from or , and R is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, sulfhydryl, cyano, nitro, methoxy, a C1-C8 alkyl, or a C3-C8 cycloalkyl. The PARP1 / CDK6 dual-target inhibitor of the present invention exhibits good effects against human breast cancer cells, and maintains a good in vitro enzyme inhibitory activity against CDK6 and PARP1. Disclosed in the present invention is the use of a CDK6 / BRD4 dual-target inhibitor in the preparation of a drug for treating PARP1 / CDK6-mediated diseases. Disclosed in the present invention is the use of a PARP1 / CDK6 dual-target inhibitor in the preparation of a drug for treating or preventing triple-negative breast cancer.

The invention discloses an antibody or an antigen binding fragment specifically binding to trop2. The antibody or the antigen binding fragment comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, the amino acid sequence of the HCDR1 is as shown in SEQ ID NO.1, the amino acid sequence of the HCDR2 is as shown in SEQ ID NO.2, the amino acid sequence of the HCDR3 is as shown in SEQ ID NO.3, the amino acid sequence of the LCDR1 is as shown in SEQ ID NO.4, the amino acid sequence of the LCDR2 is as shown in SEQ ID NO.5, and the amino acid sequence of the LCDR3 is as shown in SEQ ID NO.6. The expression condition of trop2 in human breast cancer and pancreatic cancer cell membrane tissue samples can be detected through an immunohistochemical method, and the adjoint diagnostic kit for the humanized trop2 antibody coupling medicine has the advantages of assisting in precise medication and avoiding invalid treatment.

The invention relates to the field of medicinal chemistry and cosmetics, in particular to a curcumin derivative and a preparation method and application thereof. The curcumin derivative provided by the invention has a structure as shown in a formula I. Compared with parent curcumin, the curcumin derivative provided by the invention not only improves the anti-oxidation effect, but also has the whitening and anti-aging effects which are not possessed by the parent curcumin, so that the application field range is greatly widened, and the curcumin derivative has wide application in the field of cosmetics. Moreover, the curcumin derivative provided by the invention has a good anti-tumor effect on brain glioma, human breast cancer, human lung cancer or human non-small cell lung cancer, and has wide application in the field of medicines.

This utility model discloses a two-piece bra cup with longitudinal segmentation and a bra having the cup, including a first longitudinal piece and a second longitudinal piece, wherein the thickness of the first longitudinal piece is less than the thickness of the second longitudinal piece; the first longitudinal piece is located on the side of the cup near the center gore, and the second longitudinal piece is located on the side of the cup away from the center gore; the edge of the second longitudinal piece near the first longitudinal piece is a smooth curve that rises towards the first longitudinal piece, and this edge extends from the bottom of the cup to the ear area; the first longitudinal piece covers the nipple area, and the edges of the first and second longitudinal pieces close to each other are spliced ​​and fixed to make the cup have a three-dimensional bowl-shaped structure corresponding to the curvature of the human breast. The bra cup provided by this utility model has the advantages of good lifting effect, strong side push and gathering, leak prevention, breathability and comfort, and making it appear smaller when worn.

The invention discloses a polyphenol derivative as well as a preparation method and application thereof. Pharmacological studies prove that the polyphenol derivative L96-2 provided by the invention can effectively inhibit proliferation of human breast cancer cell lines MCF-7 and MDA-MB-231 and a human nasopharyngeal carcinoma cell line C666-1, and the inhibitory activity of the polyphenol derivative L96-2 is obviously higher than that of parent compounds icaritin and isatin of the polyphenol derivative L96-2. Meanwhile, the L96-2 can be used for effectively inducing apoptosis of the MCF-7 cells. The polyphenol derivative L96-2 provided by the invention has a very good inhibition effect on breast cancer and nasopharynx cancer cells and has a very good development value, and the technology also provides a new thought and approach for synthesis and antitumor research of polyphenol derivatives. The preparation method provided by the invention has the advantages of simplicity, cheap and easily available raw materials, no special requirements on production equipment, easiness in operation, low cost and easiness in realization of industrial production.

The invention discloses a feeding bottle nipple simulating human breasts, and relates to the technical field of infant feeding appliances. The feeding bottle comprises a feeding bottle body, one side of the feeding bottle body is in threaded connection with a nipple, one side of the feeding bottle body is provided with a holding mechanism, and the holding mechanism comprises a supporting plate arranged on one side of the feeding bottle body in a sleeving mode. By means of the design of the double-layer valve plate assembly, regulation and control over the flow speed of milk are achieved, when a baby slightly sucks the milk, the thin and soft inner-layer valve plate deforms and is opened firstly, the milk slowly flows into the milk inlet pipe only through the milk inlet through hole, the low-speed state in the initial stage of breast feeding is simulated, the thick outer-layer valve plate is pushed away along with the increase of the sucking force, and the milk flows into the milk inlet pipe. The milk is rapidly output from the large-diameter channel to meet the hunger requirement, the physiological feature of'lactation reflex 'of breast milk is reproduced through the gradient deformation characteristic of the valve plate in the movement process, the bucking risk caused by the constant flow speed of a traditional nipple is effectively avoided, and the feeding comfort and efficiency are effectively improved.

A method of inhibiting cell growth in a cancer includes contacting a graphite-phase carbon nitride copper oxide and magnesium aluminum oxide (g-C3N4@CuO / MgAl2O4) nanocomposite with the cancer to inhibit growth of the cancer. The g-C3N4@CuO / MgAl2O4 nanocomposite comprises a graphite-phase carbon nitride (g-C3N4) in an amount of 2 to 18 percent by weight (wt. %), copper oxide in an amount of 1 to 10 wt. %, and magnesium aluminum oxide (MgAl2O4) in an amount of 75 to 95 wt. % based on a total weight of the g-C3N4@CuO / MgAl2O4 nanocomposite. The cancer includes cells from a cell line selected from a group consisting of a human hepatocellular carcinoma (HepG-2) cell line and a human breast carcinoma (MCF-7) cell line.

The invention discloses an automatic human mammary gland examination system based on a large language model combined with a six-axis robot, which can accurately understand a natural language instruction of a clinician by deeply fusing the natural language processing capability of the large language model, the high-precision motion control of the robot and an advanced medical image processing algorithm. A scanning path is automatically planned and executed, a two-dimensional ultrasonic image sequence is collected, a three-dimensional mammary gland model is reconstructed, the model is analyzed through an intelligent algorithm, and a structured clinical diagnosis report is automatically generated, so that full-chain automation of mammary gland ultrasonic scanning from intention understanding to report generation is realized; the standardization degree, efficiency and diagnosis consistency of mammary gland ultrasonic examination are remarkably improved, a reliable automatic solution is provided for early screening and precise diagnosis of mammary gland diseases, and the technical difficulties that in the prior art, due to manual operation, efficiency is low, repeatability is poor, and results depend on experience of operators are solved.

The invention belongs to the technical field of anti-tumor drugs, and particularly relates to an anti-tumor drug capable of inhibiting CCNB2 expression and application. The invention provides an anti-tumor drug capable of inhibiting CCNB2 expression. The anti-tumor drug refers to an anti-breast cancer drug; the antitumor drug is casein; or the antitumor drug is a composition formed by mixing casein and camptothecin according to the mass ratio of 1: (10-15); and the casein is alpha-S2 casein. The invention finds that casein can inhibit CCNB2 expression and can improve the effect of camptothecin in killing human breast cancer cell lines.

A method of treating cancer cells includes contacting the cancer cells with a CoO / CaSiO3@g-C3N4 nanocomposite material. The CoO / CaSiO3@g-C3N4 nanocomposite material includes hexagonal metal oxide nanoparticles comprising a CoO phase and a CaSiO3 phase dispersed on a matrix of g-C3N4 nanosheets. The hexagonal metal oxide nanoparticles have an average particle diameter in a range from 340 to 440 nm. The CoO / CaSiO3@g-C3N4 nanocomposite material has a percent inhibition for Human Breast Carcinoma (MCF-7) cells at least 55% inhibition in an in-vitro cellular viability assay.

The application discloses a preparation method and application of a ratio polypeptide antifouling electrochemical sensor for quantitative detection of Furin activity. The application also discloses a method for quantitative detection of Furin activity by using the prepared ratio polypeptide antifouling electrochemical sensor, in particular, application of the ratio polypeptide antifouling electrochemical sensor in detection of Furin activity in two kinds of cancer cells, i.e., human breast cancer cell MDA-MB-468 and human glioma cell U251, which overexpress Furin. Experimental results show that the ratio polypeptide antifouling electrochemical sensor disclosed by the application can effectively determine Furin in a biological sample, and the method has high accuracy, sensitivity and practicability.

The present application provides a kind of tight sportswear, comprising: body, include front body and back body;Two cups, are split structure, respectively detachably set on the inner side of the middle part of front body at the position corresponding to human breast;Collar, set in the upper part of body;And two sleeves, respectively set in the two sides of body, wherein, the outer surface of front body is provided with two curved three-dimensional inwardly converging split lines arranged symmetrically and respectively extending from top to bottom, the outer surface of back body is provided with two three-dimensional inwardly converging split lines arranged in the shape of "Gong" character, the outer surface of the rear middle part of sleeve is provided with three-dimensional joint line extending from top to bottom.

The invention belongs to the field of animal models, particularly relates to a granulomatous mastitis animal model and a construction method thereof, and aims to solve the problems of low pathological matching degree and poor repeatability of an existing model. The construction method comprises the following steps: selecting an SPF-grade BALB / c female mouse (10 weeks old, 20-22 g), preparing human mammary gland fresh lesion tissue homogenate and lesion origin staphylococcus aureus liquid (1.4 * 10 < 8 >-1.5 * 10 < 8 > CFU / mL), mixing and emulsifying with a Freund's incomplete adjuvant according to a ratio of 1: 1: 1, injecting to the third pair of mammary glands of the mouse, and completing modeling in two weeks. The pathological characteristics of the model are highly matched with human diseases, the success rate is high, the repeatability is strong, and the model can be used for GM pathogenesis research and therapeutic drug screening.

The invention discloses a thiosemicarbazone compound containing a naphthyl structure as well as a preparation method and application of the thiosemicarbazone compound. The thiosemicarbazone compound has biological activity on human breast cancer cells. The anti-tumor activity of the compound is verified through in-vitro experiments, including an inhibition effect experiment of the compound on proliferation of human breast cancer cells, an influence experiment on oxidative stress level of the breast cancer cells, an influence experiment on mitochondrial membrane potential of the breast cancer cells and an experiment for inducing apoptosis of the breast cancer cells. The thiosemicarbazone compound containing the naphthyl structure has remarkable anti-tumor activity, can effectively inhibit proliferation of human breast cancer cells, can remarkably improve the oxidative stress level of the breast cancer cells in a concentration-dependent mode, and has a close correlation between the regulation effect on the mitochondrial membrane potential of the breast cancer cells and the treatment concentration; the compound can effectively induce apoptosis of breast cancer cells, has excellent anti-breast cancer activity, and provides important candidate compounds and theoretical basis for research and development of novel anti-tumor drugs.

The present application provides a kind of bivalent platinum complex with anastrozole as ligand and its use, the structure of the bivalent platinum complex is as shown in (I).The bivalent platinum complex described in the present application has good antitumor activity.In the present method, anastrozole is reacted with potassium chloroplatinite in an organic solvent to obtain a bivalent platinum complex with anastrozole as ligand, and is applied to the antiproliferation of human breast cancer cells, showing excellent antitumor activity.

The invention provides an isoalantolactone derivative TYJ2517, namely 3, 4, 5-trimethoxybenzyl aminomethyl 3-demethyleneisoalantolactone as well as preparation and application thereof, and relates to the field of medicinal compounds, the structure of the isoalantolactone derivative is shown as follows: although many anti-cancer drugs have anti-cancer ability, the drugs generate toxicity to normal cells, and the drugs cannot generate toxicity to the normal cells. Therefore, the development of selective anti-cancer active drugs safe to normal cells is particularly important. According to the invention, TYJ2517 is synthesized, the IC50 value of the TYJ2517 to MCF-7 cells is 3.6 + / -0.8 [mu] M, and the IC50 value of the TYJ2517 to L-02 normal cells exceeds 100 [mu] M. A cell drug uptake capability test result shows that the TYJ2517 uptake capability of L-02 normal cells is low, and the TYJ2517 uptake capability of MCF-7 cancer cells is high. When the administration time is 1 hour, the selective anti-cancer index (SI) of the TYJ2517 to MCF-7 breast cancer cells and L-02 normal cells exceeds 40. Mechanism research shows that the activity of the TYJ2517 for resisting MCF-7 cancer cells is a result of inhibiting the expression quantity of PARP1 protein kinase and ROS, inducing early and late apoptosis of the MCF-7 cells and hindering migration and colony of the MCF-7 cells.

The present application belongs to the technical field of anti-tumor drugs, and particularly relates to an anti-tumor drug capable of inhibiting expression of CCNB2 and application. The present application provides an anti-tumor drug capable of inhibiting expression of CCNB2, wherein the anti-tumor drug is an anti-breast cancer drug; the anti-tumor drug is casein; or the anti-tumor drug is a composition of casein mixed with camptothecin at a mass ratio of 1:10-15; and the casein is alpha-S2 casein. It is found that casein can inhibit expression of CCNB2 and improve the effect of camptothecin on killing human breast cancer cell lines.

The invention discloses a breast pump. The breast pump comprises at least one detection module, a processing module, a breast pumping shield, a breast pumping channel part, a negative pressure mechanism and a milk storage container, the breast suction shield comprises a flange used for being attached to the breast of the human body. The breast sucking channel part is in sealed connection with the breast sucking shield and is used for accommodating a nipple and allowing milk to flow; the negative pressure mechanism is used for directly or indirectly applying negative pressure into the milk sucking channel part, and milk flows into the milk storage container through the milk sucking channel part; the detection module is used for detecting brightness change in a milk flowing path and generating detection data; the processing module is used for determining milk related parameters according to the detection data. The brightness change in a milk flowing path can be detected, and detection data can be generated; and the milk related parameters are determined according to the detection data, so that the accuracy of detecting the milk related parameters is improved.

The invention relates to the technical field of anti-tumor pharmacy. Specifically, the invention relates to an anti-tumor activity application of a compound with a structure as shown in a formula I. In-vitro MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) antitumor activity evaluation finds that the compound shown in the formula I has a remarkable inhibiting effect on the growth of human colorectal cancer HCT116 and human breast cancer cells MCF-7. The anti-tumor activity of the compound with the structure shown in the formula I is disclosed for the first time, and the compound can be used for preparing medicines for resisting colorectal cancer and other tumors and has good development and application prospects. .

A sesquiterpene acyl glycoside in rhizoma artemisiae japonicae and preparation method and application thereof. The present application belongs to the technical field of medicine, and relates to extraction and separation of a sesquiterpene acyl glycoside compound rhizoma artemisiae japonicae cembranoid I from rhizome of rhizoma artemisiae japonicae by using macroporous resin, silica gel and preparation chromatography and the like, and the preparation method is simple and easy to implement. 23 H 38 O 10 In vitro human cancer cell inhibition activity research shows that the compound has anticancer activity, including obvious inhibition on human colon cancer cells HT-29 and human breast cancer MCF-7 cells, and is expected to be developed into a new anticancer drug.

The invention discloses a polypeptide degradation agent targeting ANP32B protein as well as a preparation method and application of the polypeptide degradation agent, and belongs to the technical field of tumor targeted therapy. The polypeptide degradation agent targeting the ANP32B protein is obtained by modifying an ANP32B protein targeting binding ligand (the sequence of the ANP32B protein targeting binding ligand is shown as SEQ ID NO.1-SEQ ID NO.4 in a table 1); wherein R6 (RRRRRRR) is a cationic cell membrane penetrating peptide, and is connected with a polypeptide ligand (IAP (OH) YI) of the E3 ubiquitin ligase VHL through Linker (Acp). Experiments prove that the polypeptide degradation agent targeting the ANP32B protein has the capability of remarkably inhibiting the activity of breast cancer cells MDA-MB-231, can degrade target proteins in the cells and influence the cell cycles of the breast cancer cells MDA-MB-231, can be used for preparing anti-tumor drugs, has a good application prospect in preparation of drugs targeting human breast cancer cells, and has a wide application prospect in preparation of drugs targeting human breast cancer cells. The polypeptide can be used in another important field of polypeptide PROTAC drug development.